Edgestream Partners’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.45M | Buy |
10,373
+8,124
| +361% | +$4.27M | 0.15% | 275 |
|
|
2025
Q1 | $1.43M | Sell |
2,249
-6,573
| -75% | -$4.17M | 0.05% | 550 |
|
|
2024
Q4 | $6.28M | Buy |
8,822
+8,475
| +2,442% | +$6.04M | 0.27% | 90 |
|
|
2024
Q3 | $365K | Sell |
347
-4,870
| -93% | -$5.12M | 0.02% | 743 |
|
|
2024
Q2 | $5.48M | Sell |
5,217
-2,422
| -32% | -$2.55M | 0.26% | 99 |
|
|
2024
Q1 | $7.35M | Buy |
+7,639
| New | +$7.35M | 0.37% | 34 |
|
|
2023
Q4 | – | Sell |
-1,297
| Closed | -$1.07M | – | 1027 |
|
|
2023
Q3 | $1.07M | Buy |
1,297
+457
| +54% | +$376K | 0.09% | 380 |
|
|
2023
Q2 | $604K | Buy |
+840
| New | +$604K | 0.05% | 489 |
|
|
2023
Q1 | – | Sell |
-295
| Closed | -$213K | – | 629 |
|
|
2022
Q4 | $213K | Sell |
295
-6,351
| -96% | -$4.58M | 0.02% | 473 |
|
|
2022
Q3 | $4.58M | Buy |
6,646
+2,155
| +48% | +$1.48M | 0.35% | 88 |
|
|
2022
Q2 | $2.66M | Buy |
4,491
+815
| +22% | +$482K | 0.21% | 164 |
|
|
2022
Q1 | $2.57M | Buy |
+3,676
| New | +$2.57M | 0.2% | 167 |
|
|
2021
Q4 | – | Sell |
-1,588
| Closed | -$961K | – | 567 |
|
|
2021
Q3 | $961K | Buy |
+1,588
| New | +$961K | 0.06% | 323 |
|
|
2020
Q4 | – | Sell |
-4,764
| Closed | -$2.67M | – | 412 |
|
|
2020
Q3 | $2.67M | Buy |
+4,764
| New | +$2.67M | 0.17% | 169 |
|